Kathleen E. Morton

13.2k total citations · 6 hit papers
19 papers, 8.8k citations indexed

About

Kathleen E. Morton is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Kathleen E. Morton has authored 19 papers receiving a total of 8.8k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Immunology, 12 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Kathleen E. Morton's work include Immunotherapy and Immune Responses (13 papers), CAR-T cell therapy research (9 papers) and Virus-based gene therapy research (6 papers). Kathleen E. Morton is often cited by papers focused on Immunotherapy and Immune Responses (13 papers), CAR-T cell therapy research (9 papers) and Virus-based gene therapy research (6 papers). Kathleen E. Morton collaborates with scholars based in United States, Australia and Malaysia. Kathleen E. Morton's co-authors include Steven A. Rosenberg, Richard M. Sherry, Nicholas P. Restifo, James Chih‐Hsin Yang, Donald E. White, Suzanne L. Topalian, Douglas J. Schwartzentruber, John R. Wunderlich, Mark E. Dudley and Sharon Mavroukakis and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Kathleen E. Morton

19 papers receiving 8.6k citations

Hit Papers

Cancer Regression and Autoimmunity in Patients After Clon... 2002 2026 2010 2018 2002 2011 2003 2008 2003 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
    2002 2.2k citations Mark E. Dudley, John R. Wunderlich et al. Science profile →
  2. Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
    2011 1.6k citations Steven A. Rosenberg, James Chih‐Hsin Yang et al. Clinical Cancer Research profile →
  3. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
    2003 1.2k citations Giao Q. Phan, James Chih‐Hsin Yang et al. Proceedings of the National Academy of Sciences profile →
  4. Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
    2008 1.0k citations Mark E. Dudley, James Chih‐Hsin Yang et al. Journal of Clinical Oncology profile →
  5. Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer
    2003 573 citations James Chih‐Hsin Yang, Richard M. Sherry et al. Journal of Clinical Oncology profile →
  6. Phase I Study of the Intravenous Administration of AttenuatedSalmonella typhimuriumto Patients With Metastatic Melanoma
    2002 565 citations John Toso, Vee J. Gill et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kathleen E. Morton United States 17 6.2k 6.0k 1.9k 1.4k 718 19 8.8k
Sharon Mavroukakis United States 21 7.0k 1.1× 7.6k 1.3× 2.3k 1.2× 1.9k 1.4× 780 1.1× 36 10.5k
Daniel J. Powell United States 49 5.3k 0.9× 6.8k 1.1× 2.0k 1.0× 1.5k 1.1× 276 0.4× 118 8.8k
Zhili Zheng United States 43 5.8k 0.9× 7.8k 1.3× 3.1k 1.6× 2.5k 1.8× 302 0.4× 68 10.0k
Paul J. Spiess United States 32 6.8k 1.1× 4.8k 0.8× 2.1k 1.1× 1.2k 0.9× 498 0.7× 40 8.4k
Maryalice Stetler‐Stevenson United States 57 6.2k 1.0× 8.9k 1.5× 4.3k 2.3× 2.3k 1.6× 861 1.2× 230 15.8k
Hyam I. Levitsky United States 39 6.7k 1.1× 3.7k 0.6× 1.9k 1.0× 902 0.6× 293 0.4× 65 8.3k
Thorbald van Hall Netherlands 47 6.1k 1.0× 4.1k 0.7× 2.5k 1.3× 480 0.3× 234 0.3× 127 8.1k
Carolyn M. Laurençot United States 13 4.0k 0.6× 6.5k 1.1× 1.9k 1.0× 1.8k 1.3× 294 0.4× 16 7.6k
Daniel A. Vallera United States 52 5.3k 0.9× 3.1k 0.5× 1.7k 0.9× 507 0.4× 965 1.3× 203 8.0k
Michael J. Mastrangelo United States 46 3.1k 0.5× 3.2k 0.5× 1.9k 1.0× 739 0.5× 350 0.5× 190 6.3k

Countries citing papers authored by Kathleen E. Morton

Since Specialization
Citations

This map shows the geographic impact of Kathleen E. Morton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kathleen E. Morton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kathleen E. Morton more than expected).

Fields of papers citing papers by Kathleen E. Morton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kathleen E. Morton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kathleen E. Morton. The network helps show where Kathleen E. Morton may publish in the future.

Co-authorship network of co-authors of Kathleen E. Morton

This figure shows the co-authorship network connecting the top 25 collaborators of Kathleen E. Morton. A scholar is included among the top collaborators of Kathleen E. Morton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kathleen E. Morton. Kathleen E. Morton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Phan, Giao Q., James C. Yang, Udai S. Kammula, et al.. (2017). Routine Computer Tomography Imaging for the Detection of Recurrences in High-Risk Melanoma Patients. Annals of Surgical Oncology. 24(4). 947–951. 29 indexed citations
2.
Kochenderfer, James N., Robert Somerville, Lily Lu, et al.. (2014). Anti-CD19 CAR T Cells Administered after Low-Dose Chemotherapy Can Induce Remissions of Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma. Blood. 124(21). 550–550. 23 indexed citations
3.
Kochenderfer, James N., Mark E. Dudley, Sadik H. Kassim, et al.. (2013). Effective Treatment Of Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma With Autologous T Cells Genetically-Engineered To Express An Anti-CD19 Chimeric Antigen Receptor. Blood. 122(21). 168–168. 8 indexed citations
4.
Rosenberg, Steven A., James Chih‐Hsin Yang, Richard M. Sherry, et al.. (2011). Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy. Clinical Cancer Research. 17(13). 4550–4557. 1603 indexed citations breakdown →
5.
Dudley, Mark E., Colin Gross, Michelle M. Langhan, et al.. (2010). CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma. Clinical Cancer Research. 16(24). 6122–6131. 245 indexed citations
6.
Rosenberg, Steven A., James C. Yang, Udai S. Kammula, et al.. (2010). Different Adjuvanticity of Incomplete Freund's Adjuvant Derived From Beef or Vegetable Components in Melanoma Patients Immunized With a Peptide Vaccine. Journal of Immunotherapy. 33(6). 626–629. 19 indexed citations
7.
Dudley, Mark E., James Chih‐Hsin Yang, Richard M. Sherry, et al.. (2008). Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens. Journal of Clinical Oncology. 26(32). 5233–5239. 1017 indexed citations breakdown →
8.
Rosenberg, Steven A., Richard M. Sherry, Kathleen E. Morton, et al.. (2006). Altered CD8+ T-Cell Responses When Immunizing With Multiepitope Peptide Vaccines. Journal of Immunotherapy. 29(2). 224–231. 28 indexed citations
9.
Rosenberg, Steven A., Claude Sportès, Mojgan Ahmadzadeh, et al.. (2006). IL-7 Administration to Humans Leads to Expansion of CD8+ and CD4+ Cells but a Relative Decrease of CD4+ T-Regulatory Cells. Journal of Immunotherapy. 29(3). 313–319. 346 indexed citations
10.
Rosenberg, Steven A., Richard M. Sherry, Kathleen E. Morton, et al.. (2005). Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma. The Journal of Immunology. 175(9). 6169–6176. 365 indexed citations
11.
Phan, Giao Q., James Chih‐Hsin Yang, Richard M. Sherry, et al.. (2003). Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proceedings of the National Academy of Sciences. 100(14). 8372–8377. 1234 indexed citations breakdown →
12.
Phan, Giao Q., Christopher E. Touloukian, James C. Yang, et al.. (2003). Immunization of Patients with Metastatic Melanoma Using Both Class I- and Class II-Restricted Peptides from Melanoma-Associated Antigens. Journal of Immunotherapy. 26(4). 349–356. 91 indexed citations
13.
Rosenberg, Steven A., James C. Yang, Richard M. Sherry, et al.. (2003). Inability to Immunize Patients with Metastatic Melanoma Using Plasmid DNA Encoding the gp100 Melanoma-Melanocyte Antigen. Human Gene Therapy. 14(8). 709–714. 85 indexed citations
14.
Rosenberg, Steven A., James C. Yang, Douglas J. Schwartzentruber, et al.. (2003). Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma.. PubMed. 9(8). 2973–80. 74 indexed citations
15.
Yang, James Chih‐Hsin, Richard M. Sherry, Seth M. Steinberg, et al.. (2003). Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer. Journal of Clinical Oncology. 21(16). 3127–3132. 573 indexed citations breakdown →
16.
Toso, John, Vee J. Gill, Patrick Hwu, et al.. (2002). Phase I Study of the Intravenous Administration of AttenuatedSalmonella typhimuriumto Patients With Metastatic Melanoma. Journal of Clinical Oncology. 20(1). 142–152. 565 indexed citations breakdown →
17.
Dudley, Mark E., John R. Wunderlich, James C. Yang, et al.. (2002). A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic Melanoma. Journal of Immunotherapy. 25(3). 243–251. 274 indexed citations
18.
Dudley, Mark E., John R. Wunderlich, Paul F. Robbins, et al.. (2002). Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes. Science. 298(5594). 850–854. 2170 indexed citations breakdown →
19.
Ohnmacht, Galen A., Giao Q. Phan, Sharon Mavroukakis, et al.. (2001). A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Effect of Nystatin on the Development of Oral Irritation in Patients Receiving High-Dose Intravenous Interleukin-2. Journal of Immunotherapy. 24(2). 188–192. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sharon Mavroukakis Breakdown of academic impact, for papers by Daniel J. Powell Breakdown of academic impact, for papers by Zhili Zheng Breakdown of academic impact, for papers by Paul J. Spiess Breakdown of academic impact, for papers by Maryalice Stetler‐Stevenson Breakdown of academic impact, for papers by Hyam I. Levitsky Breakdown of academic impact, for papers by Thorbald van Hall Breakdown of academic impact, for papers by Carolyn M. Laurençot Breakdown of academic impact, for papers by Daniel A. Vallera Breakdown of academic impact, for papers by Michael J. Mastrangelo
Rankless by CCL
2026